Indaptus Therapeutics, Inc.

NasdaqCM:INDP Stock Report

Market Cap: US$9.7m

Indaptus Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of INDP?
Owner TypeNumber of SharesOwnership Percentage
Institutions605,0635.93%
Individual Insiders2,762,43527.1%
General Public6,829,38667%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 21.4%.

Top Shareholders

Top 23 shareholders own 33.02% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
13.4%
Michael Newman
1,368,356US$1.3m0%no data
11.7%
Glen Anderson
1,190,400US$1.1m0%no data
2.51%
The Vanguard Group, Inc.
256,265US$243.5k0%no data
1.99%
Jeffrey Meckler
202,859US$192.7k26.5%no data
0.98%
The Investment House LLC
99,976US$95.0k-2.4%0.01%
0.72%
Geode Capital Management, LLC
73,129US$69.5k23.3%no data
0.44%
Strategy Asset Managers, LLC
45,336US$43.1k0%0.01%
0.43%
Pine Valley Investments Limited Liability Company
43,983US$41.8k-0.23%no data
0.27%
Renaissance Technologies LLC
27,100US$25.7k1.88%no data
0.24%
Vivaldi Capital Management LP
24,000US$22.8k0%0.01%
0.15%
Citadel Advisors LLC
15,390US$14.6k-30.7%no data
0.13%
State Street Global Advisors, Inc.
13,073US$12.4k0%no data
0.047%
Tower Research Capital Europe Limited
4,812US$4.6k17.3%no data
0.0087%
Morgan Stanley, Investment Banking and Brokerage Investments
884US$839.90%no data
0.0066%
Anthony Maddaluna
670US$636.40%no data
0.0051%
UBS Asset Management AG
522US$496.0-24.6%no data
0.0039%
Bangor Savings Bank, Asset Management Arm
400US$379.70%no data
0.0015%
Walt Linscott
150US$142.40%no data
0.00063%
Wells Fargo & Company, Securities and Brokerage Investments
64US$61.00%no data
0.00059%
Bank of America Corporation, Asset Management Arm
60US$57.242.9%no data
0.00042%
Ayalon Mutual Funds Ltd.
43US$40.70%no data
0.00019%
JPMorgan Chase & Co, Brokerage and Securities Investments
19US$18.426.7%no data
0.00007%
Group One Trading LP, Asset Management Arm
7US$6.80%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/13 07:37
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Indaptus Therapeutics, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Raghuram SelvarajuH.C. Wainwright & Co.
Jason McCarthyMaxim Group